{"id":"NCT00393458","sponsor":"Novartis","briefTitle":"Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control","officialTitle":"A 52-week Treatment, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (300 and 600 µg Once Daily) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 µg Twice Daily) as an Active Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2006-10-27","resultsPosted":"2011-08-18","lastUpdate":"2011-08-18"},"enrollment":1732,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Indacaterol","otherNames":[]},{"type":"DRUG","name":"Formoterol","otherNames":[]},{"type":"DRUG","name":"Placebo to indacaterol","otherNames":[]},{"type":"DRUG","name":"Placebo to formoterol","otherNames":[]}],"arms":[{"label":"Indacaterol 300 μg plus placebo to formoterol","type":"EXPERIMENTAL"},{"label":"Indacaterol 600 μg plus placebo to formoterol","type":"EXPERIMENTAL"},{"label":"Formoterol 12 μg plus placebo to indacaterol","type":"ACTIVE_COMPARATOR"},{"label":"Placebo to indacaterol plus placebo to formoterol","type":"PLACEBO_COMPARATOR"}],"summary":"This study was designed to assess the efficacy and long-term safety of 300 and 600 µg doses of indacaterol when delivered via a single-dose dry-powder inhaler (SDDPI) in patients with chronic obstructive pulmonary disease (COPD). Patients were randomized to receive either indacaterol 300 µg once daily, indacaterol 600 µg once daily, formoterol 12 µg twice daily, or placebo.","primaryOutcome":{"measure":"Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 + 1 Day, Day 85","timeFrame":"Week 12 + 1 day, Day 85","effectByArm":[{"arm":"Indacaterol 300 μg Plus Placebo to Formoterol","deltaMin":1.48,"sd":0.012},{"arm":"Indacaterol 600 μg Plus Placebo to Formoterol","deltaMin":1.48,"sd":0.013},{"arm":"Formoterol 12 μg Plus Placebo to Indacaterol","deltaMin":1.38,"sd":0.013},{"arm":"Placebo to Indacaterol Plus Placebo to Formoterol","deltaMin":1.31,"sd":0.013}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":7},"locations":{"siteCount":183,"countries":["Argentina","Chile","Colombia","Czechia","Denmark","Ecuador","Egypt","Estonia","France","Germany","Hungary","Israel","Italy","Latvia","Lithuania","Netherlands","Peru","Romania","Russia","Slovakia","South Korea","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["22206353","22003288","21397482","21227674","20522841"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":63,"n":437},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection bacterial","Cough","Lower respiratory tract infection"]}}